Proliferation Kinetics of Subclones Carrying Point Mutations In the BCR-ABL TKD During TKI Treatment In CML Patients: Quantitative Monitoring by LD-PCR.

被引：0
|
作者：
Preuner, Sandra [1 ]
Bernroitner, Margit [1 ]
Mitterbauer, Gerlinde [2 ]
Mannhalter, Christine [2 ]
Herndlhofer, Susanne [3 ]
Sperr, Wolfgang R. [3 ]
Webersinke, Gerald [4 ]
Valent, Peter [3 ]
Lion, Thomas [1 ]
机构：
[1] CCRI, Vienna, Austria
[2] Med Univ Vienna, Dept Lab Med, Vienna, Austria
[3] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria
[4] Krankenhaus Barmherzigen Schwestern Linz, Lab Mol Biol & Tumorzytogenet, Linz, Austria
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：933 / 934
页数：2
相关论文
共 13 条
  • [1] Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR)
    Preuner, S.
    Denk, D.
    Frommlet, F.
    Nesslboeck, M.
    Lion, T.
    [J]. LEUKEMIA, 2008, 22 (10) : 1956 - 1961
  • [2] Quantitative monitoring of cell clones carrying point mutations in the BCR–ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD–PCR)
    S Preuner
    D Denk
    F Frommlet
    M Nesslboeck
    T Lion
    [J]. Leukemia, 2008, 22 : 1956 - 1961
  • [3] The kinetics of BCR-ABL transcript levels in CML patients in chronic or accelerated phase during imatinib mesylate treatment.
    Klamova, H
    Moravcova, J
    Zmekova, V
    Voglova, J
    Faber, E
    [J]. BLOOD, 2003, 102 (11) : 325B - 326B
  • [4] Analytical performance characteristics of quantitative Bcr-Abl RT-PCR monitoring of minimal residual disease in imatinib treated CML patients.
    Press, R
    Love, Z
    Tronnes, A
    Tran, T
    Kurilik, G
    Druker, B
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2004, 6 (04): : 415 - 415
  • [5] Serial molecular monitoring of BCR-ABL using quantitative real-time RT-PCR in patients with CML during therapy with STI571 (Glivec).
    Neumann, F
    Herold, C
    Habersang, K
    Kobbe, G
    Haas, R
    Gattermann, N
    Kronenwett, R
    [J]. BLOOD, 2002, 100 (11) : 332B - 332B
  • [6] Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI).
    Jabbour, Elias
    Jones, Dan
    Kantarjian, Hagop
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Giles, Francis
    Wierda, William
    Cortes, Jorge
    [J]. BLOOD, 2006, 108 (11) : 225A - 225A
  • [7] The value of monitoring CML and ALL patients harboring the bCR-ABL translocation by serial real-time quantitative PCR after allogeneic stem cell transplantation
    Gärtner, F
    Rebelo, M
    Potthoff, K
    Zehbe, S
    Waller, C
    Bertz, H
    Finke, J
    [J]. BONE MARROW TRANSPLANTATION, 2002, 29 : S122 - S123
  • [8] Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during imatinib treatment
    Galimberti, S
    Cervetti, G
    Guerrini, F
    Testi, R
    Pacini, S
    Fazzi, R
    Simi, P
    Petrini, M
    [J]. CANCER GENETICS AND CYTOGENETICS, 2005, 162 (01) : 57 - 62
  • [9] Predictive role of Bcr-Abl expression monitoring using real time quantitative RT-PCR in imatinib mesylate treated CML patients in chronic phase.
    Bories, D
    Chami, F
    Dapremont, V
    Dumont, V
    Debert, C
    Jodar, M
    Tulliez, N
    Van den Akker, J
    Perot, C
    [J]. BLOOD, 2002, 100 (11) : 333B - 333B
  • [10] Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
    Branford, S
    Rudzki, Z
    Parkinson, I
    Grigg, A
    Taylor, K
    Seymour, JF
    Durrant, S
    Browett, P
    Schwarer, AP
    Arthur, C
    Catalano, J
    Leahy, MF
    Filshie, R
    Bradstock, K
    Herrmann, R
    Joske, D
    Lynch, K
    Hughes, T
    [J]. BLOOD, 2004, 104 (09) : 2926 - 2932
12